NCT02044146View on ClinicalTrials.gov

A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

October 31, 2016

Study Completion Date

June 30, 2017

Conditions

Acute Coronary SyndromePercutaneous Coronary Intervention

Interventions

DRUG

Ticagrelor, Prasugrel, Clopidogrel

Trial Locations (2)

K1Y4W7

University of Ottawa Heart Institute, Ottawa

H1T1C8

Montreal Heart Institute, Montreal

All Listed Sponsors

collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

Ottawa Heart Institute Research Corporation

OTHER

NCT02044146 - A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk | Biotech Hunter | Biotech Hunter